BC Sepsis Network

COVID-19: Pathophysiology, Clinical Management, Therapeutic Evidence & Ongoing Trials
May 13, 2020 | 0900 - 1000 PT | Zoom Lecture

Recently, the BC COVID-19 Therapeutics Committee (CTC) published new Clinical Practice Guidance for Antimicrobial and Immunomodulatory Therapy in Adult Patients with COVID-19. In this University of British Columbia webinar, CTC members Adam Thomas and David Sweet will discuss the unique pathophysiology of COVID-19, how it alters clinical management and review the latest therapeutic evidence.


In this session, participants will have the chance to:

  • Discuss the unique pathophysiology of COVID-19 including alterations to traditional ARDS definitions with L and H phenotype respiratory failure, cytokine storm and prothrombotic states;
  • Understand how this unique pathophysiology of COVID-19 alters clinical management;
  • Review associated COVID-19 specific sequela of organ dysfunction outside of respiratory failure; and
  • Review up-to-date evidence on various COVID-19 antiviral and immunomodulating therapy and the RCTs currently planned or underway.


Adam Thomas

Emergency Physician, Royal Jubilee Hospital

Critical Care Fellow, Vancouver

Member, COVID-19 Therapeutics Committee

David Sweet

Critical Care Medicine, Vancouver General Hospital

ICU Student/Resident/Associate Director, Vancouver General Hospital

Clinical Lead for Sespis, BC Patient Safety & Quality Council

Clinical Associate Professor, University of British Columbia

Chair, COVID-19 Therapeutics Committee

How to Join

UBC Virtual Grand Rounds will be held over Zoom. Access this link early to test your video and audio.

For technical Support, call 1-877-266-0666 and select option 2.

For more all other inquiries, email chantel.archibald@ubc.ca or visit the UBC website here.

Copyright © 2020 BCPSQC. All rights reserved.